Compositions and methods for tissue repair
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsShalesh Kaushal, Mani Annamalai
Life of this patent
Estimating the term…
Abstract
The invention generally provides compositions and methods for the repair or regeneration of a tissue or organ in need thereof.
Claims27
A method for tissue repair or regeneration, the method comprising contacting a cell with an effective amount of an agent having at least two activities selected from the group consisting of i) inhibition of hsp-90 biological activity;
- ii) mobilization of a bone marrow derived stem cell;
- iii) inhibition of apoptosis;
- and iv) modulation of an immune response.
-12. (canceled)
(canceled)
A pharmaceutical composition for tissue repair or regeneration comprising an effective amount of an agent having at least two activities selected from the group consisting of i) inhibition of hsp-90 biological activity;
- ii) mobilization of a bone marrow derived stem cell;
- iii) inhibition of apoptosis;
- and iv) modulation of an immune response in a pharmaceutically acceptable excipient.
-27. (canceled)
A method of activating or mobilizing a bone marrow derived cell in a subject in need thereof, the method comprising
- (a) administering to the subject an effective amount of an agent selected from the group consisting of triptolide, a Tryptigerium derivative of Formula 1-106, oridonin, geldanamycin, celastrol, dihydrocelastrol, dihydrocelastrol diacetate, pristimerol, 17-AAG, oridonin, valproic acid, a combination of celastrol and geldanamycin, a combination of celastrol and 17-AAG, a combination of celastrol and triptolide, and structural or functional analogs thereof;
- and
- (b) administering an effective amount of TE-140 peptide, GM-CSF and/or Stem Cell Factor, wherein the amount of said agent and GM-CSF and/or Stem Cell Factor is sufficient to activate or mobilize a bone marrow derived cell in the subject.
-43. (canceled)
A method of inhibiting pancreatic cell death in a subject, the method comprising contacting a pancreatic cell at risk of cell death with an agent having at least two activities selected from the group consisting of i) inhibition of hsp-90 biological activity;
- ii) mobilization of a bone marrow derived stem cell;
- iii) inhibition of apoptosis;
- and iv) modulation of an immune response.
(canceled)
A method of treating or preventing diabetes in a subject, the method comprising administering an effective amount of a compound selected from the group consisting of triptolide, a Tryptigerium derivative of Formula 1-106, oridonin, geldanamycin, celastrol, dihydrocelastrol, dihydrocelastrol diacetate, pristimerol, 17-AAG, oridonin, valproic acid, a combination of celastrol and geldanamycin, a combination of celastrol and 17-AAG, a combination of celastrol and triptolide, and a combination of celastrol and a TE-140 peptide, or structural or functional analogs, thereby treating or preventing diabetes.
-52. (canceled)
-92. (canceled)
Dependencies are inferred from the claim text.